维普期刊资源整合服务平台（V6.5）

28篇 您的检索式：作者名="Ford HE"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort显示文摘	Ian Jacobs Aleksandra Gentry-Maharaj Matthew Burnell Ranjit Manchanda Naveena Singh Aarti Sharma Andy Ryan Mourad W Seif Nazar N Amso Gillian Turner Carol Brunell Gwendolen Fletcher Rani Rangar Kathy Ford Keith Godfrey Alberto Lopes David Oram Jonathan He	2011	Lancet Oncology2011，，1：	2
2	Do- cetaxel versus active symptom control for refractory oesophagogas- tric adenocarcinoma ( COUGAR-02 ) : an open-label, phase 3 randomised controlled trial 显示文摘	FORD HE MARSHALLA BRIDGEWATER JA etal	2014	Lancet Oneol2014，15，1：	1
3	Combination of raltitrexed with other cytotoxic agents : rationale and preclinical observations 显示文摘	Jackman AL Kimbell R Ford HE	1999	Eur J Cancer1999，35，1：	1
4	Combination of raltitrexed with other cytotoxic agent: rational and preclinical observations显示文摘	Jackman AL Kimbell R Ford HE	1999	Eur J Cancer1999，35，1：	1
5	A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy显示文摘	Gregory C W He B Johnson R T Ford O H Mohler J L French M F Wilson E M	2001	Cancer Research2001，6，1：	1
6	Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed显示文摘	Farrugia DC Ford HE Cunningham D	2003	Glin Cancer Res2003，9，4：	1
7	Doeetaxel versus ac- tive symptom control for refractory oesophagogastric adenoearei- noma (COUGAR-02): an open-label, phase 3 randomised con- trolled trial显示文摘	Ford HE Marshall A Bridgewater JA	2014	Lancet Onc012014，15，1：	1
8	Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment显示文摘	Ashby DR Ford HE Wynne KJ	2009	Kidney lnt2009，76，2：	1
9	Combination of raltitrexed with other cytotoxic agents:rationale and preclinical observa- tions 显示文摘	Jackman AL Kimbell R Ford HE	1999	Eur J Cancer1999，35，1：	1
10	Docetaxel ver- sus active symptom control for refractory oesophagogastric ad- enocarcinoma (COUGAR-02) : an open-label, phase 3 ran- domised controlled trial 显示文摘	Ford HE Marshall A Bridgewater JA	2014	Lancet Oneol2014，15，1：	1
11	Sustained appetite improvement in malnourished dialysis patients by daily Ghrelin treatment显示文摘	Ashby DR Ford HE Wynne KJ		0，，：	1
12	Docetaxel versus ac- tire symptom control for refractory oesophagogastric ad (COUGAR-02) : an open-label, phase 3 randomised 显示文摘	Ford HE Marshall A Bridgewater JA	2014	The Lancet Oncology2014，15，1：	1
13	Docetaxel versus ac- tive symptom control for refractory oesophagogastric adenocarcino- ma(COUGAR - 02 ) : An open - label, phase 3 randomised con- trolled trial显示文摘	Ford HE Marshall A Bridgewater JA	2014	Lancet Onco12014，15，1：	1
14	Sustained appetite improvement in malnourished dialysis patients by dally ghrelin treatment 显示文摘	Ashby DR Ford HE Wynne KJ	2009	Kidney Int2009，76，2：	1
15	Combination of raltit- rexed with other cytotoxic agents: rationale and preclinical obser- vations显示文摘	Jackman AL Kimbell R Ford HE	1999	Eur J Cancer1999，35，1：	1
16	Combination of raltitrexed with other cytotoxic agent : rationale and preclinical observations 显示文摘	Jackman AL Kimbell R Ford HE	1999	EurJ Cancer1999，35，1：	1
17	Combination of raltitrexed with other cytotoxic agents:Rationale and preclinical observations显示文摘	Jackman AL Kimbell R Ford HE	1999	Eur J Cancer1999，35，1：	1
18	Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma(COUGAR-02) : an open-label, phase 3 randomised controlled trial显示文摘	Ford HE Marshall A Bridgewater JA	2014	Lancet Oncol2014，15，1：	1
19	Combination of rahitrexed with other cytotoxic agents: rationale and preclinical observations 显示文摘	Jackman AL Kimbell R Ford HE	1999	Eur J Cancer1999，35，1：	1
20	Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment显示文摘	Ashby DR Ford HE Wynne KJ	2009	Kidney Int2009，76，2：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示